Citi raised the firm’s price target on Alcon (ALC) to CHF 101 from CHF 99 and keeps a Buy rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon’s Stock Boosted by FDA Approval of Innovative Dry Eye Drug TRYPTYR
- Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target
- Alcon Secures FDA Approval for TRYPTYR to Treat Dry Eye Disease
- Alcon’s Tryptyr approved by FDA for signs and symptoms of Dry Eye Disease
- Alcon upgraded to Buy from Hold at Kepler Cheuvreux